Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of PD 0332334 in Generalized Anxiety Disorder
NCT00658008Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Apr 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of imagabalin in generalized anxiety disorder (GAD), sponsored by Pfizer. Started Apr 2008; status: terminated.
02
Drugs
imagabalin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00658008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658008.